Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 111-119, May 2006

Gastrointestinal stromal tumors: Differential diagnosis

  • Nancy Dow, MD

      Affiliations

    • Division of Gastrointestinal Pathology, Armed Forces Institute of Pathology, Washington, DC
    • Corresponding Author InformationAddress reprint requests and correspondence: Nancy Dow, MD, Division of Gastrointestinal Pathology, Armed Forces Institute of Pathology, 6825 16th Street, N.W. Bldg, 54, Rm. 3003, Washington, DC 20306-6000.
  • ,
  • Georgeta Giblen, MD

      Affiliations

    • Division of Gastrointestinal Pathology, Armed Forces Institute of Pathology, Washington, DC
  • ,
  • Leslie H. Sobin, MD

      Affiliations

    • Division of Gastrointestinal Pathology, Armed Forces Institute of Pathology, Washington, DC
  • ,
  • Markku Miettinen, MD

      Affiliations

    • Division of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC.

Availability of KIT tyrosine kinase inhibitors for specific treatment of GISTs has magnified the importance of accurate differential diagnosis of GIST from other tumors occurring in the GI tract and abdomen. The general problems in this distinction include histological mimicry of other mesenchymal tumors with GIST, occasional KIT-negativity of GIST, and KIT-positivity of non-GISTs. Up to 5% to 10% gastric GISTs and <2% of intestinal GISTs can be KIT-negative. The identification of these tumors as GISTs is based on knowledge of the spectrum of GIST morphology, and can be supported by molecular diagnosis of KIT and PDGFRA mutations (the latter pertain to gastric tumors). True smooth muscle tumors (rare in GI tract except in esophagus and colon) can be separated from GISTs by the eosinophilic tinctorial quality of tumor cells, positivity for smooth muscle markers, and negativity for KIT. Desmoids can form large GIST-like masses, but are composed of spindled or stellate-shaped cells in a densely collagenous stroma. Negativity for KIT and nuclear positivity for beta-catenin are differentiating features. GI schwannomas, melanoma, and rare primary clear cell sarcoma are S100-positive, usually with characteristic histology. The latter two can be KIT-positive. KIT-positive non-GISTs include some sarcomas, especially angiosarcoma and Ewing sarcoma, extramedullary myeloid tumor, seminoma, and a few carcinomas, notably small cell carcinoma of lung. Spurious KIT-positivity, seen with some polyclonal KIT antibodies, has been a source of confusion leading to probable false-positive results in fibroblastic tumors and occasional other sarcomas, such as leiomyosarcomas. Integration of histological features with carefully standardized immunohistochemistry, supported by KIT and PDGFRA mutation analysis, is the cornerstone of state-of-the art differential diagnosis of GIST. To comprehensively capture all GISTs, KIT immunostains should be performed on all unclassified epithelioid and mesenchymal tumors of the abdomen.

Keywords: GIST, Differential diagnosis, KIT, PDGFRA, Immunohistochemistry, Sarcoma, Desmoid, Inflammatory myofibroblastic tumor, Melanoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The opinions and assertions contained herein are the expressed views of the authors and are not to be construed as official or reflecting the views of the Departments of the Army or Defense.

PII: S0740-2570(06)00144-4

doi:10.1053/j.semdp.2006.09.002

Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 111-119, May 2006